4,156 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Brown Miller Wealth Management LLC

Brown Miller Wealth Management LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,156 shares of the company’s stock, valued at approximately $533,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Pacific Center for Financial Services raised its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $25,000. CNB Bank bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $26,000. Tyler Stone Wealth Management increased its holdings in Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after buying an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. raised its position in Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after acquiring an additional 150 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $1.75 on Friday, hitting $142.74. The stock had a trading volume of 2,757,544 shares, compared to its average volume of 3,502,773. The stock has a market cap of $640.55 billion, a price-to-earnings ratio of 49.22, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $148.15. The business’s 50 day moving average is $135.00 and its two-hundred day moving average is $123.54.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Analysts forecast that Novo Nordisk A/S will post 3.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price objective on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Argus lifted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. The Goldman Sachs Group began coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.